Glimepirid Lek

Glimepirid Lek is an oral medication that contains the active ingredient glimepiride, a second‑generation sulfonylurea used to manage blood glucose. It is marketed in the European Union and is supplied as tablets, although the specific strength is not listed. As a prescription‑only product, Glimepirid Lek belongs to the antidiabetic, oral hypoglycemic therapeutic class and works by stimulating insulin release from pancreatic beta cells in patients with type 2 diabetes.

Glimepirid Lek is indicated for the oral treatment of type 2 diabetes mellitus when diet, exercise, and other non‑pharmacologic measures are insufficient to achieve glycemic control.

- Improves fasting and post‑prandial blood glucose levels. - Can be used as monotherapy in patients newly diagnosed with type 2 diabetes. - May be combined with metformin or other oral antidiabetic agents for enhanced effect. - Suitable for adults who are able to swallow tablets. - May be considered when other sulfonylureas are not tolerated.

The safety profile of glimepiride includes a range of adverse effects that vary in frequency and severity.

Common: - Mild to moderate hypoglycemia, especially when meals are missed. - Weight gain due to increased insulin activity. - Nausea, abdominal discomfort, or dyspepsia. - Dizziness or headache.

Serious: - Severe allergic reactions such as rash, itching, swelling, or anaphylaxis. - Prolonged hypoglycemia leading to loss of consciousness or seizures.

Before starting Glimepirid Lek, certain clinical considerations and warnings should be reviewed to minimize risk.

- Assess renal and hepatic function; dose adjustment may be needed. - Avoid use in patients with known hypersensitivity to sulfonylureas. - Caution in the elderly due to increased risk of hypoglycemia. - Monitor blood glucose regularly, especially when initiating therapy or changing dose. - Use with caution during pregnancy or breastfeeding; benefits must outweigh potential risks. - Consider cardiovascular status, as sulfonylureas may affect ischemic preconditioning.

Glimepirid Lek can interact with several medicines, influencing its glucose‑lowering effect or increasing the risk of adverse events.

Avoid: - Concurrent use with other sulfonylureas or meglitinides (additive hypoglycemia risk). - Co‑administration with strong CYP2C9 inhibitors (e.g., fluconazole) may raise glimepiride levels. - Use with monoamine oxidase inhibitors may affect glucose control.

Use with caution: - Combination with insulin or other insulin secretagogues requires dose adjustments. - Concomitant beta‑blockers may mask hypoglycemia symptoms. - Loop diuretics can affect plasma glucose and potassium balance. - NSAIDs may impair renal function, influencing drug clearance.